Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Companysort icon Description Status Initial Date
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing ground-breaking tools in high definition diagnostics. Private 2007 View Profile
<a href="/venture-capital/all-companies/rubius-therapeutics">Rubius Therapeutics</a> Pioneering a new therapeutic modality using genetically modified red blood cells to create Red-Cell Therapeutics™ with the potential to treat diverse areas of high unmet medical need. Private 2014 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Private 2008 View Profile
<a href="/venture-capital/all-companies/seres-therapeutics">Seres Therapeutics</a> Developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. Public 2012 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. Private 2007 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Developing innovative diagnostic products to improve patient health. Public 2006 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing novel treatments for urologic diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/tarveda-therapeutics-inc">Tarveda Therapeutics Inc.</a> Tarveda develops Pentarins™, which are novel miniaturized biologic drug conjugates uniquely designed to target, penetrate and treat solid tumors. Private 2012 View Profile
<a href="/venture-capital/all-companies/transmedics-inc">TransMedics, Inc.</a> Extending the life saving benefits of organ transplantation to patients suffering from end-stage organ failure. Private 2010 View Profile
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile